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Cachexia is the involuntary loss of muscle and adipose tissue that strongly affects
mortality and treatment efficacy in patients with cancer or chronic inflammatory disease.
Currently, no specific treatments or interventions are available for patients developing
this disorder. Given the well-documented involvement of pro-inflammatory cytokines in
muscle and fat metabolism in physiological responses and in the pathophysiology of
chronic inflammatory disease and cancer, considerable interest has revolved around
their role in mediating cachexia. This has been supported by association studies
that report increased levels of pro-inflammatory cytokines such as tumor necrosis
factor-alpha (TNF-α) and interleukin-6 (IL-6) in some, but not all, cancers and in
chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD)
and rheumatoid arthritis (RA). In addition, preclinical studies including animal disease
models have provided a substantial body of evidence implicating a causal contribution
of systemic inflammation to cachexia. The presence of inflammatory cytokines can
affect skeletal muscle through several direct mechanisms, relying on activation of the
corresponding receptor expressed by muscle, and resulting in inhibition of muscle
protein synthesis (MPS), elevation of catabolic activity through the ubiquitin-proteasomal
system (UPS) and autophagy, and impairment of myogenesis. Additionally, systemic
inflammatory mediators indirectly contribute to muscle wasting through dysregulation
of tissue and organ systems, including GCs via the hypothalamus-pituitary-adrenal
(HPA) axis, the digestive system leading to anorexia-cachexia, and alterations in liver
and adipocyte behavior, which subsequently impact on muscle. Finally, myokines
secreted by skeletal muscle itself in response to inflammation have been implicated
as autocrine and endocrine mediators of cachexia, as well as potential modulators of
this debilitating condition. While inflammation has been shown to play a pivotal role in
cachexia development, further understanding how these cytokines contribute to disease
progression is required to reveal biomarkers or diagnostic tools to help identify at risk
patients, or enable the design of targeted therapies to prevent or delay the progression
of cachexia.
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CACHEXIA IN CANCER AND CHRONIC
DISEASE
Cachexia is a complex metabolic syndrome resulting in
severe weight loss, anorexia, and asthenia that occurs in
many types of cancer and chronic inflammatory diseases
(Evans et al., 2008). The nature of this weight loss is
characterized by a pronounced systemic muscle wasting
and weakness and includes marked loss of fat mass.
Consequently, cachexia remains a significant co-morbidity
in many diseases increasing mortality, reducing quality
of life, and representing a major burden on healthcare
providers. However, despite its impact in human disease
the mechanisms that underpin cachexia remain poorly defined.
In this review, we provide an overview and explore the latest
insights into the contribution of systemic inflammation in
cachexia, including both direct and indirect mechanisms of
inflammatory muscle wasting.
Cachexia is highly prevalent in various types of cancers, with
estimates of 30% in lung and head and neck cancer, and 41–
45% in pancreatic and liver cancer, respectively (Anker et al.,
2019). In addition, a high prevalence of cachexia has also been
described for patients with chronic illnesses, including chronic
heart failure (CHF; 10–39%) (Anker et al., 1997; Valentova et al.,
2020), chronic kidney disease (CKD; 30–60%) (Mak and Cheung,
2006), chronic obstructive pulmonary disease (COPD; 5–33%)
(Koehler et al., 2007; Sanders et al., 2016; Kwan et al., 2019),
and rheumatoid arthritis (RA; 19–32%) (Santo et al., 2018)
(although RA is often debated as being a cachectic disease as
weight loss is not always a defining feature; Roubenoff, 2009).
Cachexia is associated with decreased survival and quality of life
in these conditions (Anker and Sharma, 2002; Reid et al., 2010;
McDonald et al., 2019), and poor clinical outcome as is illustrated
by increased postoperative mortality for cancer (Pausch et al.,
2012) and CHF (Abel et al., 1976) and decreased response
to radiation-, chemo-, and immunotherapy in the presence of
cachexia (Sealy et al., 2020).
Diagnostic criteria for cachexia include weight loss in the
presence of underlying illness of >5% in ≤12 months, or weight
loss >2% in individuals with a low body-mass index (<20 kg/m2)
or low muscle mass (Fearon et al., 2011), and the presence of
decreased muscle strength, fatigue or anorexia, and abnormal
biochemistry (Evans et al., 2008). Interestingly, the latter refers
to the presence of increased inflammatory serum markers like
interleukin-6 (IL-6) and C-reactive protein (CRP), suggesting
inflammation as a shared characteristic of cachexia in these
distinct conditions. Indeed, several clinical studies have reported
elevated levels of inflammatory markers in cancer patients with
cachexia. In non-small cell lung carcinoma, CRP, IL-6, and
interleukin 8 (IL-8) serum levels were increased in cachectic
compared to non-cachectic lung cancer patients (Op den Kamp
et al., 2013). Riccardi et al. (2020) recently highlighted changes
in plasma concentrations of markers of systemic inflammation
in patients with cancer cachexia compared to weight-stable
cancer patients. A positive correlation between pro-inflammatory
cytokines and fatty acid lipid profile was reported in patients with
gastrointestinal cancer cachexia, accompanied with augmented
levels of CRP, and elevated levels of pro-inflammatory cytokines
IL-6, tumor necrosis factor-alpha (TNF-α), and IL-8 (Riccardi
et al., 2020). In patients with gastro-esophageal cancer, multiple
regression analysis identified dietary intake and serum CRP
concentrations as independent variables in determining the
degree of weight loss, with a higher predicted effect than disease
stage (Deans et al., 2009). Based on these and other studies,
it is now recognized that a systemic inflammatory response is
associated with weight and muscle loss and poorer outcomes in
patients with cancer (Arends et al., 2017), and can be applied in
identifying the various stages of cachexia (Douglas and McMillan,
2014). A recent systematic review by Abbass et al. (2019) revealed
a consistent correlation between systemic inflammation and low
skeletal muscle index determined through CT and DEXA scans
in patients with various types of cancer, further implicating a
link between inflammation and skeletal muscle mass loss in
cancer cachexia.
Similarly, a correlation between cachexia and inflammation
has also been described in chronic diseases. Cachectic patients
with CHF often exhibit elevated levels of pro-inflammatory
cytokines such as TNF-α, IL-6, interleukin-1 (IL-1), and
interferon-γ (IFN-γ), in addition to glucocorticoids (GCs)
(Anker et al., 1999). These molecules act as signaling ligands
to directly and indirectly impact muscle and adipose tissue
metabolism in favor of wasting (Jackman and Kandarian, 2004).
Patients with cardiac cachexia also exhibit elevated levels of
Angiotensin II (Ang II), which has been shown to increase
the levels of these pro-inflammatory cytokines (Brink et al.,
2001; Zhang et al., 2009), and induce cachexia (Brink et al.,
2001). In CKD patients, increased expression of TNF-α and
IL-6 is detected in skeletal muscle (Zhang et al., 2020), and
cachexia is accompanied by increases in circulating TNF-α
and IL-6 in addition to CRP (Stenvinkel et al., 2005), which
often occur in the presence of malnutrition, and therefore
is referred to as malnutrition-inflammation-cachexia syndrome
(Kalantar-Zadeh, 2005). In patients with CKD, cachexia was not
only associated with elevated levels of CRP, but also increased
fibrinogen, and reduced cross-sectional area (CSA) of muscle
fibers and fat mass (Zhang et al., 2013). Cachexia development
in COPD has also been associated with the presence of systemic
inflammation. COPD patients with unintentional weight loss
and skeletal muscle mass loss showed elevated serum cytokine
levels including TNF-α and IL-6 compared to stable-weight
patients (Di Francia et al., 1994; Eid et al., 2001). Disease-specific
characteristics of COPD have been implicated as the driver of
inflammation, such as increased TNF-α levels as a result of
hypoxemia resulting from reduced lung function (Takabatake
et al., 2000), or increased systemic inflammation secondary
to disease exacerbations in COPD (Wedzicha et al., 2000).
Respiratory infections and subsequent pulmonary inflammation
are a frequent cause of exacerbation, and these episodes are
accompanied by catabolic changes in skeletal muscle (Crul et al.,
2010), and considered as a potentially accelerating phase in
COPD cachexia (Abdulai et al., 2018). It is well established that
patients with RA have elevated levels of inflammatory cytokines,
specifically TNF-α, IL-1β, and IL-6, and are found directly at
the synovial joint or found to be released into the plasma,
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stimulating both local and systemic inflammation (Saxne et al.,
1988; Shingu et al., 1993; Chikanza et al., 1995). The latter have
been implicated in rheumatoid cachexia, with reports of reduced
lean body mass (LBM) correlating with elevated serum levels of
IL-6 and CRP (Munro and Capell, 1997; Engvall et al., 2008)
In other chronic inflammatory conditions than RA, like Crohn’s
disease, correlations with weight loss have also been described
(Nakashima et al., 1998; Bossola et al., 2000; Mantovani et al.,
2001; Dulger et al., 2004; Tas et al., 2005; Baker et al., 2016),
indicating that the relation between systemic inflammation
and cachexia may extend beyond the diseases described here.
Importantly, a correlation between circulating inflammatory
cytokines and cachexia may not be detected in all patients, as
a result of the rapid systemic clearance, or the presence of
additional triggers of muscle and weight loss in these complex
conditions, such as malnutrition in CDK (Mak and Cheung,
2006) and COPD (Creutzberg et al., 2003), or hypoxemia
in COPD (Ceelen et al., 2014). In addition, exacerbations in
conditions like RA, COPD, and Crohn’s disease activity may
be associated with transient increases in systemic inflammation,
followed by sustained loss of body and muscle mass, which are
not recovered as a result of other disease-related impairments in,
e.g., inactivity, hypoxemia, or malnutrition (Ceelen et al., 2014).
The observed correlation between inflammation with cachexia
across the various diseases described above is the basis for
including serum markers of increased inflammation as a criterion
in the definition of cachexia. Importantly, beyond its use as
a clinical hallmark, inflammation has been investigated as
a potential driver of cachexia, fueling a number of studies
investigating the causal involvement of inflammation and
underlying mechanisms by which it contributes to cachexia. An
overview of these reports is presented below. To facilitate their
discussion, a description of the processes that govern muscle mass
is provided first.
Cellular Processes That Determine
Muscle Mass
Maintenance and modulation of skeletal muscle mass has
been attributed to two processes: protein turnover and
myonuclear turnover. Under normal conditions, these
processes are maintained in homeostasis, however during
skeletal muscle wasting the balance within these processes
shift in favor of muscle wasting, through the inhibition
of muscle protein synthesis (MPS), activation of muscle
protein degradation, reduction in myonuclear accretion, or
increased myonuclear loss. Protein turnover is a dynamic
process determined by protein synthesis and degradation
and is mediated through transcriptional, translational,
and post-translational mechanisms (Booth et al., 1998).
One important regulatory circuit of protein turnover is the
insulin growth factor-1(IGF-1)–phosphoinositide−3−kinase
(PI3K)–Akt/protein kinase B (PKB)–mammalian target
of rapamycin (mTOR) pathway. Akt is the key mediator
stimulating protein synthesis through mTOR activation, while
inhibiting protein degradation through phosphorylation of
transcription factor (TF) Forkhead box O (FoxO), leading
to its cytoplasmic retention where it is inactive (Schiaffino
et al., 2013). Translational capacity in skeletal muscle is
regulated through eukaryotic initiation factors (eIFs) and
ribosomal S6 kinase (P70S6K). Formation of the eIF4F
complex is a rate-limiting step in initiation of the mRNA
translation process (Gingras et al., 1999), while phosphorylation
of P70S6K facilitates ribosomal biogenesis and translation
(Hay and Sonenberg, 2004).
Skeletal muscle is the largest latent reservoir of amino acids,
which are mobilized by increased proteolysis of mainly muscle
contractile proteins to provide energy or precursors for protein
synthesis to other vital organs (Attaix et al., 2005). Muscle protein
degradation increases as a physiological response to starvation
but is also activated during pathological catabolic states that
accompany inflammation and cachexia. Control of muscle mass
is highly regulated by proteolytic enzyme systems including
the ubiquitin-proteasomal system (UPS), autophagy-lysosomal
pathway (ALP), caspases, and calpains. The UPS is involved
in the removal of specific proteins for degradation following
marking with ubiquitin through specific a sequential process
catalyzed by ubiquitin-activating enzymes (E1), conjugating
enzymes (E2), and ligating enzymes (E3) (Sorensen, 2018). It
is an enzymatic process initiated by E1 enzymes activating the
ubiquitin which is transferred to the E2 ubiquitin-conjugating
enzyme (Ciechanover, 2005). The E2 ubiquitin complex binds to
E3 protein ligases that recognize substrate proteins that will be
ubiquitinated. Polyubiquitinated proteins are transferred in an
ATP-dependent manner to 26S proteasome complexes in which
they are degraded. E3 Ub ligases are postulated as rate-limiting
factors in this pathway (Scicchitano et al., 2018), and a number
of muscle enriched E3 Ub-ligases have been described, including
Atrogin-1 and MuRF1. The ALP is essential for removal of
misfolded or aggregated proteins and damaged parts of the cell
to prevent accumulation of toxic or abnormal organelles and
proteins. In addition, it enables the breakdown of proteins to
produce amino acids by skeletal muscle that can be utilized
in other tissues during catabolic periods, such as starvation
(Sandri, 2010). There are three types of autophagy described
in mammals; macroautophagy, microautophagy, and chaperone-
mediated autophagy. Although all three processes are distinct
from one another, these mechanisms ultimately lead to lysosomal
degradation of cargo and recycling of breakdown products
(Bonaldo and Sandri, 2013). Calpains and caspases are families
of cysteine proteases, and their proteolytic activity is increased
during cellular necrosis or apoptosis. They have been implicated
in suspending cell function through disabling signal transduction
molecules by enzymatic cleavage at specific amino acid residues
in a host of cells (Wang, 2000), but their overall relevance to
increased muscle proteolysis in muscle atrophy is not yet clear.
As will be highlighted in subsequent sections, both decreases in
MPS and increases in proteolysis have been implicated in the loss
of muscle mass in cachexia.
Myonuclear turnover is another important process involved
in muscle homeostasis and is the balance between myonuclear
accretion and apoptosis. Myonuclear accretion is the final step
in post-natal myogenesis (Schiaffino et al., 2013), and relies on
satellite cells (SCs), the local precursor cells of skeletal muscle
Frontiers in Physiology | www.frontiersin.org 3 November 2020 | Volume 11 | Article 597675
fphys-11-597675 November 12, 2020 Time: 15:14 # 4
Webster et al. Inflammation and Atrophy in Cachexia
(Pallafacchina et al., 2013). During muscle regeneration, SCs
are activated and proliferate, which occurs through asymmetric
cell division, resulting in two distinct myoblast populations.
A portion of these myoblasts returns into quiescence to prevent
depletion of precursor cells. The other population of myoblasts
terminally differentiate and fuse with muscle fibers (or myotubes
in vitro). Committed SCs highly express PAX7 and MYF5,
which decreases during differentiation. MyoD is an important
myogenic regulator during proliferation and early differentiation.
Conversely, MyoG is most important in late differentiation,
fusion and myotube formation (Bentzinger et al., 2012). Changes
in the intricate regulation of SC activation, proliferation,
and differentiation by triggers of muscle wasting, including
inflammation, may result in impaired post-natal myogenesis,
contributing to muscle atrophy. Myonuclear accretion seems to
be impaired in cachexia as shown in animal studies (Ceelen et al.,
2018a). In addition, in cachectic mice a reduced proliferation
and differentiation capability of SCs was reported, resulting
in myofibers not being able to regenerate or maintain their
myofiber size by myonuclear accretion leading to atrophy
(Inaba et al., 2018).
Evidence for a role of inflammation as a driver of cachexia
and underlying mechanisms have mainly been collected in
experimental models, including cultured skeletal muscle cells,
animals exposed to controlled inflammatory conditions, and
rodents in which diseases associated with cachexia are modeled.
The marked benefit of these models is they can be deployed
in experimental designs to address inflammation as a causative
factor of cachexia. Moreover, they are instrumental to dissect
direct and indirect effects of inflammation contributing to muscle
atrophy, and provide fundamental insight in the underlying
mechanisms, including the signaling pathways activated by
inflammation and intra-cellular processes that cause muscle to
atrophy. From these perspectives, the literature investigating the
role of systemic inflammation in cachexia is discussed below.
Associations Between Systemic
Inflammation and Cachexia in Disease
Models
Various experimental disease models have provided incremental
associative evidence to imply inflammation in the etiology
of muscle wasting. In murine cancer cachexia models, the
concurrent presence of systemic inflammation and loss of muscle
and fat tissue has extensively been document. In Walker-
256 tumor-bearing rats increased systemic inflammation was
observed with animals presenting elevated plasma TNF-α and
IL-6 compared to non-tumor-bearing control animals (Cella
et al., 2020). These also showed increased gene expression
and protein levels of MuRF1 and Atrogin-1 in hind limb
muscles (Cella et al., 2020). Similar observations were reported
in an orthotopic mouse model of bladder cancer, in which
increased levels of inflammatory cytokines TNF-α, IL-6, and
IL-1β, and activation of pro-inflammatory pathways including
NF-κB were detected in muscles of urothelial tumor-bearing
animals. These observations were paralleled by downregulation
of Akt- and FoxO3 phosphorylation levels, suggestive of a
shift toward catabolic signaling (Chen et al., 2016). Zhuang
et al. (2016) showed that Atrogin-1 and MuRF1 levels were
significantly increased in colon-26 (C26)-bearing mice suffering
from cachexia, along with significant increases in circulating and
muscle TNF-α and IL-6, whereas expression levels of anabolic
IGF-1 were decreased. A recent study by Chiappalupi et al.
(2020) showed that body and muscle weight loss in mice with
subcutaneously growing Lewis Lung Carcinoma (LLC) cells, was
accompanied by elevated serum cytokine levels, including IL-
1β, IL-6, IL-10, IFN-γ, and TNF-α. Interestingly, this study
highlighted the importance of receptor for advanced glycation
end-products (RAGE) in sustaining the inflammatory response
in tumor-bearing mice, with RAGE null mice protected against
increased systemic inflammation, body weight loss, and muscle
weight loss (Chiappalupi et al., 2020).
The association between inflammation and cachexia has
also been extensively explored in non-cancer, inflammatory
models. Jepson et al. (1986) showed administration of LPS in
fed rats resulted in inflammation and reduced muscle weights
accompanied by decreased MPS and increased proteolysis of
skeletal muscle. This study also showed fasted untreated animals
had reduced MPS, yet fasting combined with LPS treatment
exacerbated this reduction, therefore highlighting that reduced
food intake alone in response to LPS was not the sole cause of
skeletal muscle loss (Jepson et al., 1986). Therefore, these results
show that the anorectic effects of LPS alone do not fully account
for the muscle atrophy observed in this model, and therefore
suggest anorexia-independent effects of inflammation in muscle
wasting (Jepson et al., 1986). In line, Langen et al. (2012)
showed animals with LPS-induced pulmonary and systemic
inflammation exhibited more skeletal muscle atrophy than pair-
fed control mice, implying an additional effect of inflammation
beyond anorexia or hypophagia. Similarly, LPS administered
to rats to induce sepsis resulted in reduced body weights
and muscle weights which could not be fully attributed to
hypophagia. Here, inflammation was implicated as the primary
diver of skeletal muscle loss independently of anorexia (Macallan
et al., 1996). Mice with LPS and pepsin aspiration pneumonia-
induced inflammation showed increased levels of IL-1β, IL-6,
and MCP-1 in diaphragm and limb muscles in combination
with reduced myofiber size (Komatsu et al., 2018). In this
model, increased levels of MuRF1 and Atrogin-1 in muscles
were shown to be indicative of elevated UPS activity and
calpain and caspase-3 pathway activation (Komatsu et al.,
2018). Langen et al. (2012) showed pulmonary inflammation
by intratracheal instillation of LPS in mice resulted in a rapid
increase in circulating pro-inflammatory cytokines such as TNF-
α, IL-1β, IL-6, and CXCL1, which preceded the loss of skeletal
muscle mass in these animals. In both models of pulmonary
inflammation, besides evidence for UPS-mediated proteolysis,
increased Bnip3, LC3B, and Gabarapl1 expression levels were
measured in skeletal muscle, suggesting elevated ALP activity
in lung inflammation-induced muscle atrophy (Komatsu et al.,
2018). Similar findings were reported in murine models of
CHF. Here cardiomyopathy, characterized by increased pro-
inflammatory macrophages infiltration in cardiac muscle and
elevated serum IL-6 levels resulted in elevated skeletal muscle
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TNF-α and CXCR4 expression and reduced fiber CSA, indicative
of inflammatory myopathy (Lynch et al., 2017; Song et al.,
2019). Furthermore, CHF was shown to reduce skeletal muscle
regeneration following muscle damage (Song et al., 2019).
Despite the diversity in primary pathology, and the degree
and kinetics by which cachexia develops in these disease
models, systemic inflammation and its preceding and correlation
with muscle wasting appear a consistent factor beyond simple
association in cachexia.
(Pre)clinical Evidence for Inflammation
as a Cause of Cachexia in Disease
Several in vivo studies have highlighted the importance of
specific pro-inflammatory cytokines or activation of specific
inflammatory pathways in muscle wasting through genetic
or pharmaceutical inhibition, showing causal evidence
that inflammation is a required component of atrophy in
pathological models.
In models of cancer cachexia, e.g., mice or rats with
methylcholanthrene-induced sarcoma (MCG-101) or in LLC
tumor bearing mice, skeletal muscle wasting was alleviated
through the blockade of the apex pro-inflammatory cytokine
TNF-α through administration of anti-TNF antibodies (Sherry
et al., 1989; Torelli et al., 1999). In addition, intra-muscularly
inoculated LLC-tumor bearing WT mice displayed increased
protein degradation and loss of muscle mass, which was
prevented in transgenic littermates overexpressing the soluble
TNF receptor type 1 protein (sTNF-R1) to inhibit the actions
of local or circulating TNF-α (Llovera et al., 1998). While
this study implies a causal contribution of TNF-α in skeletal
muscle atrophy, this may result from indirect effects of TNF-
α by increasing other cytokines such as IL-6 that contribute to
cachexia development by impacting on skeletal muscle. Indeed,
IL-6 has been implicated in cancer cachexia. ApcMin/+ mice
with cancer cachexia showed significant muscle wasting in
presence of a 10-fold increase of serum IL-6 levels compared
to control groups (Baltgalvis et al., 2009). In addition, host-IL-
6 was shown to be required in the development of cachexia
in these mice, with ApcMin/+/IL-6−/− mice showing reduced
tumor burden and muscle wasting (Baltgalvis et al., 2008).
Furthermore, administration of anti-murine IL−6 receptor
antibody to C−26−bearing mice attenuated muscle wasting,
in support of IL-6-dependent muscle atrophy in colon cancer
cachexia (Fujita et al., 1996).
Administration of both anti-TNF-α and an IL1-receptor
antagonists in models of cancer cachexia also shows evidence
of preservation of body weight and improved food intake
compared to untreated tumor-bearing controls, suggesting a
common mechanism for both cytokines (Gelin et al., 1991).
Furthermore, anti-TNF-α and anti-IL1-R treatment also reduced
tumor growth, suggesting indirect effects of inflammation as a
determinant of tumor burden in driving atrophy (Gelin et al.,
1991). Similarly, in a rat RA model, administration of soluble
TNF receptor I (sTNFRI) as a TNF blocking strategy improved
body weight, but also food intake compared to control groups,
implying that anti-inflammatory modulation may contribute to
bodyweight maintenance by blocking anorexic effects (Granado
et al., 2006). In line with that notion, in a cardiac cachexia
rodent model, anti-TNF-α treatment significantly reduced losses
in body and skeletal muscle mass, partly through reduced
UPS activation through the attenuation of anorexia (Steffen
et al., 2008). Finally, in a model of cachexia induced by
Trypanosoma cruzi, mice treated with anti-TNF-α antibodies
displayed significant attenuation of weight loss, while anti-IL-
6 and anti-IFN-γ antibodies had no such effect. In addition,
this protection of weight loss occurred during the acute phases
of infection and was only transient in nature, suggesting early
administration of anti-TNF therapies may be more effective in
the early phases of cachexia (Truyens et al., 1995).
The concept of a causal role of pro-inflammatory cytokines
mediating cachexia in humans has only been addressed very
limitedly and only in a few pathological conditions, using targeted
therapeutics that deplete specific cytokines such as TNF-α and IL-
6. In contrast to the experimental models, the effects of TNF-α
blockade in cancer cachexia, while complicated by the diversity
of disease etiologies, and limitations due to the actions of the
corresponding treatments on tumor immunity, have proven less
promising. Here a number of studies examining different cancer
patient cohorts have failed to identify any meaningful changes
in body weights, LBM, or muscular function (determined by
6 min walk test) in response to anti-TNF-α interventions (Jatoi
et al., 2007, 2010; Wiedenmann et al., 2008; Gueta et al., 2010).
Studies examining anti-IL-6 in cachexia are limited. One case
report in a patient with large-cell carcinoma of the lung and
cancer cachexia demonstrated improved inflammatory outcomes
with reduced serum IL-6 after prednisolone treatment, with
no further deterioration in cachexia parameters (Ando et al.,
2013). While these studies are frequently complicated by poor
accrual, recruitment, and interactions with other disease-related
complications and between ongoing therapeutic interventions,
thus far the causal involvement of inflammation in muscle
atrophy during cancer cachexia has been difficult to assess in
clinical studies.
In COPD, several TNF blocking agents have reached phase-
II clinical trials, but these have been complicated by initial
concerns related to increased incidence of cancer compared
to the placebo control treatment arms (Rennard et al., 2007),
which were later contested in a long-term follow-up analysis
(Rennard et al., 2013). While the original rationale for anti-TNF
treatment was to intervene in the lung pathology, more recent
insights suggest that specific groups of patients, in particular
COPD patients with cachexia may benefit from TNF-blocking
agents (Rennard et al., 2013). Studies appropriately designed to
assess this remain to be initiated, however. In contrast, TNF-
α blockade has proven highly effective in the management
of chronic inflammatory disease such as RA (Saxne et al.,
1988). It must be noted that in RA, evaluating the direct
contribution of inflammation on muscle mass and function
is complicated by the actions of these treatments on disease
activity, which reduce pain and allow for improvements in
dietary intake and physical activity. Here, several such studies
failed to report meaningful correlations in changes in body
composition, in response to anti-TNF-α treatments over short
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durations (Marcora et al., 2006; Elkan et al., 2009). These
studies are complicated by side by side comparison with
disease modifying anti-rheumatic drugs such as methotrexate,
which possess their own anti-inflammatory immunomodulatory
effects that may mask muscle protective actions. However,
studies examining anti-TNF-α intervention in RA over longer
periods revealed improvement in body weight, BMI, total
and fat mass relative to patients receiving standard disease
management treatment (Chen et al., 2013; Toussirot et al., 2014).
Moreover, promising results have been observed in alternative
chronic inflammatory arthropathies and inflammatory diseases
such as ankylosing spondylitis and Crohn’s disease. Here,
in ankylosing spondylitis, improvement in muscle strength
parameters was reported following anti-TNF-α intervention,
while increases in both muscle volume and strength were
evident in patients with Crohn’s (Subramaniam et al., 2015;
Demirkapi et al., 2017).
Despite the ambiguous evidence from clinical studies, the
preclinical disease models strongly support a causal relationship
between inflammation and cachexia. The extent to which actions
of inflammation depend on interactions with other pathology-
related alterations, or whether inflammation per se is sufficient
to induce cachexia, is addressed in different experimental
models described next.
Causal Evidence Implying Inflammation
as a Driver of Skeletal Muscle Atrophy
Many in vivo studies have shown that the induction of an
inflammatory state by TNF-α infusion initiate the development
of cachexia, resulting in reduced food intake, loss of bodyweight,
and skeletal muscle loss (Tracey et al., 1988; Llovera et al.,
1993). In addition, implantation of a continuously TNF-α
producing tumor cell line into mice, elicited cachexia and
weight loss, with reduced food intake, compared to the
control, non-secreting tumor cell line (Oliff et al., 1987).
TNF-α has also shown to suppress the IGF-1 pathway and
cause insulin resistance, which may also play a role in
the dysregulation of macronutrient uptake and utilization
(Broussard et al., 2003; Frost et al., 2003). Mice inoculated
with tumors that overexpress IFN-γ presented with severe
cachexia, and IFN-γ inhibition prior to inoculation attenuated
body weight loss (Matthys et al., 1991), implying IFN-γ
secretion rather than other tumor-dependent effects in the
development of tissue depletion in this model. In mice
inoculated with tumor cells expressing Fn14, a receptor for the
inflammatory cytokine tumor necrosis factor-like weak inducer
of apoptosis (TWEAK), significant cachexia development and
reduced survival rates were observed (Johnston et al., 2015).
Moreover, anti-Fn14 monoclonal antibodies prevented cachexia
development, while tumor growth rate being reduced, implying
local or reciprocal effects of anti-Fn14 on tumor growth and
cachexia (Johnston et al., 2015). In line, chronic administration
or muscle-specific transgenic overexpression of TWEAK in
mice resulted in reduced body and skeletal muscle weight
with an associated increased activity of UPS and NF-κB
(Dogra et al., 2007).
Alternatively, the release of pro-inflammatory cytokines
is triggered in models of sepsis. Schakman et al. (2012)
induced inflammation in rats through LPS injection, which
lead to a loss of body and muscle weight. IGF-1 levels were
significantly reduced, and accompanied by an upregulation of
FoxO1, Atrogin-1, and MuRF1. In a similar model, identical
findings were reported, as well as increased muscle TNF-α
expression (Dehoux et al., 2003), indicative of local inflammatory
signaling and activation of proteolysis in this model of
muscle wasting. Increased levels of systemic inflammatory
cytokines may result from spill over from an inflamed site,
as is the cause for pulmonary inflammation. Ceelen et al.
(2018b) evoked pulmonary inflammation in mice, which
resulted in systemic inflammation and muscle atrophy, with
accompanying of UPS-mediated proteolysis and upregulation
of E3 ligases MuRF1 and Atrogin-1. Interestingly, there were
no additive effects of body weight loss and muscle wasting
in emphysematous mice compared to control groups after
LPS exposure, and can therefore be concluded muscle atrophy
was a direct consequence of the pulmonary inflammation and
not affected by the presence of emphysema (Ceelen et al.,
2017). This group also showed evoking repetitive pulmonary
inflammation in emphysematous mice, mimicking recurrent
acute exacerbations in COPD, resulted in sustained muscle
atrophy, which was associated with markers of impaired
muscle regeneration, with altered myogenic signaling and
reduced fusion capacity (Ceelen et al., 2018a). In line, chronic
pulmonary inflammation in transgenic mice with lung-specific
overexpression of TNF resulted in muscle atrophy and an
impaired muscle regenerative response compared to WT
littermate control animals (Langen et al., 2006).
Taken together, these studies demonstrate inflammation
is sufficient to drive muscle wasting beyond the context of
disease-induced cachexia. However, these models cannot
distinguish direct from indirect effects, i.e., requiring
involvement of another tissue or intermediary paracrine
or autocrine signal, impacting on the intramuscular
processes that drive muscle mass loss in cachexia. As
such understanding is instrumental for development of
intervention strategies, an extensive number of studies focused
on identifying the intracellular pathways responsible for
sensing inflammatory signals and transducing these into
atrophy responses.
DIRECT EFFECTS OF INFLAMMATION:
SIGNALING PATHWAYS AND
ACTIVATING LIGANDS RESPONSIBLE
FOR RELAYING DIRECT, MUSCLE
ATROPHY-INDUCING EFFECTS OF
INFLAMMATION
The direct effects of inflammation on skeletal muscle require
receptor-mediated activation of intra-muscular signaling
pathways. Various signaling pathways activated by inflammatory
cytokines, or inflammation-associated ligands have been
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implicated in muscle atrophy through regulation of muscle
protein turnover or myonuclear turnover. These pathways and
the corresponding activating ligands (overview in Figure 1)
that have been implicated in muscle atrophy are described
in this section, including their impact on muscle protein and
myonuclear turnover.
NF-κB-Signaling
Nuclear factor-κB (NF-κB) is a TF, and activation of classical
NF-κB signaling occurs in response to various inflammatory
cytokines (e.g., IL-1 and TNF-α) and oxidative stress. The former
act through corresponding receptor binding and activation,
and recruitment of adaptor proteins, resulting in I-kappa-B
kinase (IKK) activation and culminating in NF-κB nuclear
translocation. TNF receptor-associated factors (TRAF) is a family
of intracellular adaptor proteins that interact with the surface
receptors TNFR-1 and -2, Toll-like receptor 4 (TLR4), and IL-1R.
TNF-α receptor adaptor protein 6 (TRAF6) not only integrates
upstream inflammatory signals, but is central to the activation
of many signaling pathways including NF-κB and MAPK in
response to cytokines (Paul et al., 2010; Miao et al., 2017). Activity
if this adaptor protein is elevated in cachectic LLC-bearing mice,
while TRAF6 depletion attenuated muscle wasting in tumor
bearing mice (Paul et al., 2010). Downstream, NF-κB activation
has been implicated as an important step in inflammation-
induced muscle wasting. Inhibition of NF−κB alleviates the
cytokine-driven atrophy of muscle, thus highlighting NF-κB in
the direct effects of inflammatory stimuli in muscle wasting
(Ladner et al., 2003). Prevention of muscle NF-κB activation in
genetically modified mice attenuated muscle wasting in a model
of pulmonary inflammation-induced systemic inflammation
(Langen et al., 2012). Similarly, both, pharmacological (Miao
et al., 2017) and muscle-specific genetic (Cai et al., 2004)
inhibition of NF-κB prevented muscle wasting in tumor
bearing mice, indicating the importance of this TF in cancer
cachexia. Conversely, muscle specific activation of the NF−κB
pathway in transgenic mice resulted in profound muscle atrophy
(Cai et al., 2004).
NF-κB activation has been implicated in increasing UPS
proteolytic activity through the expression of E3 Ub-ligases
genes Atrogin-1 and MuRF1 (Kandarian and Jackman, 2005;
Dillon et al., 2007; Schiaffino et al., 2013). In lung inflammation-
induced muscle atrophy, genetic inhibition of skeletal NF−κB
inhibited the increases in MuRF1 expression (Langen et al., 2012),
which was shown as a required step for muscle wasting in a
similar model using MuRF1 knock-out (KO) mice (Files et al.,
2012). In line, upregulation of MuRF1 was also required for
muscle atrophy observed in response to muscle specific activation
of the NF−κB pathway in transgenic mice (Cai et al., 2004).
Furthermore, NF-κB, through Akt inhibition, leads to elevated
FoxO activity which stimulates the expression of UPS- and ALP-
related genes, such as LC3 and Bnip3 (Hanna et al., 2012).
Additionally, NF-κB prevents myoblast cell cycle exit, reduces
MyoD and Myf-5 protein abundance and activity (Langen et al.,
2004), and decreases MyoD mRNA expression (Guttridge et al.,
2000), leading to impaired post-natal myogenesis (Guttridge
et al., 2000; Langen et al., 2001, 2004). Furthermore, in vitro
and in vivo studies have also shown that serum factors from
cachectic mice and patients, in an NF-κB-dependent manner,
induce expression of the self-renewing factor Pax7, implying
NF-kB inhibits myogenic differentiation through sustained Pax7
expression (He et al., 2013).
Muscle wasting-inducing properties of the inflammatory
cytokines TNF-α and IL-1 have mainly been attributed
to receptor-mediated activation of NF-κB, and involve
increased proteolysis as well as impaired myogenesis, Several
in vitro studies have shown inflammatory cytokine TNF-α
administration in C2C12 myocytes leads to activation of NF−κB
signaling (Guttridge et al., 2000; Langen et al., 2001). The NF−κB
inhibitor PDTC inhibited upregulation of MuRF1 induced by
TNF-α medium in vitro through inhibition of NF−κB indicating
the importance of this signaling pathway. TNF-α induced
upregulation of the catabolic genes Atrogin-1 and MuRF1
parallel to inducing myotube atrophy in differentiated C2C12
cells (Li et al., 2005). In L6 and C2C12 myotubes treated with
TNF-α, decreased eIF3f translation initiation factor abundance
and increased Atrogin-1 levels were observed during myotube
atrophy, suggestive of decreased protein synthesis and elevated
proteolysis, respectively (De Larichaudy et al., 2012). Genetic
inhibition of NF-κB was also reported to prevent TNF-induced
myotube atrophy (Liu et al., 2010), although in later work by
this group TNF-α was postulated to act via p38 to increase
Atrogin-1 and MuRF1 (Li et al., 2005), which was confirmed in
another study for TNF-α-induced Atrogin-1 in C2C12 myotubes
(Chiappalupi et al., 2020). IL-1 is an inflammatory cytokine
which actions overlap with TNF-α, and can be elevated during
cancer cachexia (Cederholm et al., 1997). C2C12 incubation
with either IL-1α or IL-1β resulted in reduced myotube size
and activation of NF-κB signaling, in turn leading to increased
Atrogin-1 and MuRF1 expression (Li et al., 2009). Another
activator of NF-kB signaling implicated in muscle atrophy
concerns the cytokine TWEAK and its receptor fibroblast
growth factor inducible 14 (Fn14). TWEAK has been shown
to be capable of inducing inflammation, which was reduced in
Fn14-deficient mice, through unknown mechanisms, implying
TWEAK as a feed-forward signal for an inflammatory state
(Girgenrath et al., 2006). Following TWEAK binding to Fn14
it can activate various signaling modules through its adaptor
proteins (e.g., TRAF6), leading to NF-κB and MAPK activation
(Sato et al., 2014). Myotubes incubated with TWEAK show
increased NF-κB activation (Dogra et al., 2007; Bhatnagar and
Kumar, 2012), MuRF1 and ALP-related genes such as Beclin1,
and activation of caspases. Inhibition of MuRF1, autophagy, or
caspase-3 blocked the TWEAK-induced degradation of MyHC
and myotube atrophy (Bhatnagar et al., 2012). Furthermore,
TWEAK incubation in vitro can inhibit Akt phosphorylation,
leading to reduced protein synthesis while stimulating protein
degradation (Dogra et al., 2007).
In vivo, TNF-α overexpression has been shown to impair
proliferative and myogenic responses during muscle regeneration
(Langen et al., 2006). In differentiating C2C12 myocytes,
activation of NF-κB by TNF-α incubation lead to the inhibition
of MyoD through destabilization of MyoD mRNA (Guttridge
et al., 2000) and MyoD protein (Langen et al., 2004). Another
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FIGURE 1 | Signaling pathways activated by inflammatory ligands involved in cachexia-related muscle atrophy. Colors refer to transcription factors (orange),
proteolytic signaling (orange), kinases (dark blue), adaptor proteins (light blue), and cell surface receptors (pink). HMGB1, high mobility group box 1; S100B, S100
calcium-binding protein B; RAGE, receptor for advanced glycation endproducts; ActRIIB, activin receptor type IIB; TWEAK, tumor necrosis factor-like weak inducer
of apoptosis; Fn14, fibroblast growth factor-inducible 14; TNFα, tumor necrosis factor-α; IL, interleukin; JAK, Janus kinase; STAT, signal transducers and activators
of transcription; TRAF, TNF receptor associated factor; FoxO, Forkhead box transcription factors; mTOR, mammalian target of rapamycin; IKK, IκB kinase; NF-κB,
nuclear factor-κB; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; MyoD, myoblast determination protein 1; MyoG, myogenin; MRF4,
myogenic regulatory factor; AP-1, activator protein 1; MuRF-1, muscle RING-finger protein-1; Bnip3, BCL2 interacting protein 3; Gabarapl1, GABA type A receptor
associated protein like 1.
study showed that when using the NF−κB inhibitor PDTC the
induction of atrogenes which may have contributed to MyoD
and MyHC proteolysis was inhibited in cells incubated with
TNF-α (Miao et al., 2017). TNF-α has been shown to stimulate
myoblast proliferation at the expense of differentiation in vitro in
an NF-κB-dependent manner (Otis et al., 2014). Similarly, it was
also shown IL-1 induces proliferation which was inhibited after
inhibiting NF-κB, indicating this effect is NF-κB mediated (Otis
et al., 2014). Two other studies also showed IL-1 stimulated NF-
κB activity in vitro, which also showed increases in proliferation
of both primary and C2C12 myoblasts, highlighting IL-1 impacts
on myogenic activity in skeletal muscle cells (Langen et al., 2001;
Otis et al., 2014). TWEAK has also been shown to convey anti-
differentiation and pro-proliferation actions through inducing
sustained NF-κB activation and MyoD degradation in addition
to reduced expression levels of MyoD and MyoG in vitro (Dogra
et al., 2006; Girgenrath et al., 2006; Winkles, 2008).
Besides direct atrophy-inducing effects of TNF signaling
through NF-kB, autocrine activation of parallel pathways in
muscle have also been described. Treatment of TNF-α alone or
combined with IFN-γ increased the expression of RAGE and its
ligands S100B, and HMGB1 in C2C12 myotubes (Chiappalupi
et al., 2020). Subsequent atrophy of myotubes and increased
Atrogin-1 and MuRF1 mRNA expression levels required the
presence of RAGE, and involved JAK-STAT activation, implying
an autocrine signaling circuit downstream of TNF-induced p38
MAPK and NF-κB activity.
JAK/STAT-Signaling
The JAK/STAT pathway is activated by type I (IFN-α/β), type
II (IFN-γ), IL-2, and IL-6 receptor stimulation (Schindler
et al., 2007). IL-6 binding to the IL-6r-Gp130 receptor complex
results in the recruitment to the intracellular domain of
the receptor, and subsequent activation of the JAK tyrosine
kinase. After binding, JAK proteins undergo a conformational
change, dimerize, and activate the STAT proteins through
phosphorylation. Subsequently homo- or hetero-dimerization
of STAT proteins is followed by translocation to the nucleus
(Moresi et al., 2019). STAT transcriptional activation contributes
to muscle wasting through various mechanisms. It stimulates
CCAAT/enhancer binding protein (C/EBPδ) expression and
activity, which in turn increases myostatin, MAFbx/Atrogin-1,
MuRF1, and caspase-3 expression in myofibers (Haddad et al.,
2005; Zhang et al., 2013; Silva et al., 2015), enhancing muscle
proteolysis. Moreover, increased myostatin expression resulting
from STAT-C/EBPδ activation suppresses post-natal myogenesis
(Zhang et al., 2013), which in turn may negatively affect muscle
mass maintenance. Furthermore, STAT was documented to
regulate gene transcription by interaction with FoxO and NF-κB
(Oh et al., 2012; Yoon et al., 2012).
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Interleukin-6 is a pleiotropic cytokine which can induce
several intra-cellular signaling pathways including JAK/STAT in a
variety of cells types. Intra-cellular signaling through the binding
of IL-6 to the IL-6R in turn associates with the transmembrane
protein Gp130, which is ubiquitously expressed in most cells.
The soluble form of IL-6R (sIL-6R) is found in most bodily
fluids and also binds to IL-6, further increasing the range of
target tissues for IL-6 as the IL-6-sIL-6R complex has the ability
to bind and activate to Gp130 on any cell, this is known as
“trans- signaling” (Heinrich et al., 2003). IL-6 has been implicated
as a core mediator of cancer cachexia. Indeed, systemic IL-6
concentrations increase with intestinal tumor development in
ApcMin/+ mice and is associated with elevated p-STAT-3 and
Atrogin-1 mRNA levels (Baltgalvis et al., 2009). In addition, host-
IL-6 was shown to be required in the development of cachexia
in these mice, with ApcMin/+/IL-6−/− mice showing reduced
tumor burden and muscle wasting (Baltgalvis et al., 2008).
In line, increased circulating IL-6 levels and elevated STAT-3
signaling were detected in skeletal muscle of C26 cachectic mice,
and inhibition of STAT-3 attenuated muscle atrophy in vitro
and in vivo (Bonetto et al., 2012). Blockade of IL-6R through
administration of an anti-murine IL-6R antibody in C26-bearing
mice also showed attenuated muscle loss and reduced expression
of cathepsin B and L in muscle compared to tumor-bearing
controls (Fujita et al., 1996), highlighting the requirement of
IL-6 and IL-6 signaling in this experimental model of cancer
cachexia. Conversely, overexpression of human IL-6 increased
expression of proteasomal subunits cathepsins B and L in muscle
and induced muscle atrophy in transgenic mice (Tsujinaka et al.,
1995), highlighting that chronic elevation of circulating IL-6
is sufficient to cause muscle wasting. In support of a role for
increased proteolysis, intra-peritoneal injections of IL-6 lead to
increased muscle atrophy in rats measured by tyrosine and 3-
methylhistidine release (Goodman, 1994). In addition, reduced
phosphorylation of PS6K1, indicative of reduced translational
capacity, and protein synthesis have been reported in muscles
infused with IL-6 (Haddad et al., 2005). Local IL-6 infusion
into the TA muscle decreased total and myofibrillar protein
content in rats (Haddad et al., 2005), suggesting that atrophy-
inducing effects of IL-6 are the result of direct actions of IL-6
on skeletal muscle. In support of this, C2C12 myotubes treated
with recombinant IL-6 did show reduced myotube diameter,
reduced mTOR and 4EBP-1 phosphorylation, and increased
STAT3 phosphorylation and Atrogin-1 transcription, showing
IL-6 suppresses mTOR and therefore reducing protein synthesis,
in addition to increasing atrogene expression (White et al.,
2013). However, other studies have shown little effect of IL-6
on skeletal muscle both in vivo and in vitro (García-Martínez
et al., 1994; Ebisui et al., 1995), which may be explained by
differences in IL-6 levels, shorter exposure regiments, or the
pleiotropic nature of IL-6 in skeletal muscle, e.g., the source of
IL-6 (Daou, 2020).
Gp130 has been implicated as the main cellular receptor in
skeletal muscle to mediate the IL-6 effects in cancer cachexia.
Mice injected with LLC with a genetic deletion of Gp130
specifically in skeletal muscle showed attenuated muscle wasting
compared to WT controls, primarily through reduced STAT
signaling and atrogin-1 and FoxO3 activation (Puppa et al.,
2014). In line, hyperactivation of STAT3 signaling through Gp130
activation in gp130F/F knock-in mice with a k-Ras-driven lung
carcinoma developed cachexia with reduced muscle and fat mass
and reduced life expectancy compared to k-Ras mice without
Gp130 hyperactivation (Miller et al., 2017). Although these
results show the importance of the activation of Gp130 and
STAT signaling in cancer cachexia, Gp130 activation is not solely
restricted to IL-6.
Leukemia inhibitory factor (LIF) has also recently been
identified as a cytokine, which activates the same receptor
as IL-6 and also mediates skeletal muscle atrophy through
STAT and ERK signaling (Seto et al., 2015). Seto et al.
showed in a murine model of C26 colon carcinoma with
muscle atrophy, serum levels of LIF increased in parallel to
tumor development. LIF was actively secreted by C26 tumor
cells, whereas TNF-α and IL-6 were not, and incubation of
C2C12 myotubes with LIF was sufficient to induce atrophy.
Conversely, LIF inhibition in tumor cell conditioned media
(CM) prevented CM-induced myotube atrophy in vitro, while
genetic inactivation of STAT3 in myofibers was sufficient to
suppress atrophy in vivo (Seto et al., 2015). RAGE is part of
the immunoglobulin superfamily and known as a key mediator
of several pathological processes. It is activated by ligands
including high mobility group box 1 (HMGB1) and the S100
calcium−binding protein B (S100B), which are secreted by
various cell types, including tumor cells and damaged myofibers
(Chiappalupi et al., 2020). Furthermore, inflammatory cytokines
activate a feed-forward RAGE signaling loop by inducing
HMGB1, S100B, and RAGE expression in skeletal muscles
(Chiappalupi et al., 2020). Its potential relevance to cancer
cachexia is suggested by increased serum levels of S100B and
HMGB1 in the serum of cancer patients (Miyamoto et al., 2016;
Chiappalupi et al., 2020), and highlighted by the observation that
LLC-bearing RAGE/KO mice displayed delayed body and muscle
weight loss, reduced Atrogin-1 and MuRF1 expression levels, and
prolonged survival time compared to WT mice. The cytosolic
domain of RAGE connects to JAK/STAT3 signaling, implicated
in increased protein degradation and decreased differentiation,
but has also been reported to activate the tyrosine kinase
protein, Src, which is implicated in several other downstream
signaling hubs, such as ERK1/2, p38 MAPK, JNK, and NF-κB
(Riuzzi et al., 2018).
MAPK Signaling
The MAPK pathway controls growth and stress responses
in a myriad of cell types, including skeletal muscle. MAPK
signaling is activated by cellular stress, growth factors, and
pro-inflammatory cytokines (e.g., IL-1 and TNF-α) (Zhang
and Liu, 2002). The MAPK family of proteins consists of
four distinct signaling pathways, namely, extracellular signal-
regulated kinases 1 and 2 (ERK1/2), p38 MAPK, c-Jun NH2-
terminal kinases (JNK), and ERK5 (Kramer and Goodyear, 2007).
p38 MAPK mediates upregulation of MuRF1 and Atrogin-1 in
response to TNF-α by an unknown mechanism (Li et al., 2005;
Chiappalupi et al., 2020). IL-1 signaling has also been shown to
stimulate phosphorylation of p38 MAPK, leading to increased
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atrogin-1 expression, independent of Akt/FoxO signaling (Li
et al., 2009). Furthermore, p38 phosphorylates MRF4, thus
inhibiting the expression of selective myogenic genes in late
myogenesis, and antagonizes the JNK proliferation-promoting
pathway (Suelves et al., 2004; Perdiguero et al., 2007). JNK
mediates AP-1 activation, which is a signaling molecule that
controls proliferation and differentiation through transcriptional
regulation of cell-cycle regulators such as cyclin D1, cyclin
A, and cyclin E (Kyaw et al., 2002; Hess et al., 2004), and
has been implicated in muscle atrophy responses (Liu et al.,
2010). When treated with TNF-α, C2C12 increased p-ERK
in differentiating myoblasts, which correlated with suppressed
MyoD and MyoG levels, and reduced accretion of myosin heavy
chain content. Administration of the ERK inhibitor PD98059
to C2C12 cells prevented this inhibitory effect of TNF-α on
myogenic differentiation (Penna et al., 2010).
SMAD-Signaling
The smad pathway is activated by multiple ligands, but in the
context of muscle mass control, Myostatin/GDF8, a member of
the transforming growth factor-β (TGF-β) family, is the best
described (Lee and Jun, 2019), next to GDF11 (Egerman et al.,
2015) and Activin-A (Trendelenburg et al., 2012). Myostatin
is a myokine, and its autocrine and paracrine effects act as a
break on skeletal muscle growth. Myostatin has been found
to be associated with cancer cachexia and its expression is
stimulated through the JAK/STAT pathway (Costelli et al., 2008;
Zhang et al., 2013). This positions Smad signaling secondary
to transcriptional activation of Mstn by inflammatory cues.
Binding of myostatin to ActRIIB results in the phosphorylation
of Smad2/3 (El Shafey et al., 2016) and activation of Smad
signaling, which reduces p-Akt levels (Trendelenburg et al.,
2009), consequently activating caspase-3 and FoxO, and resulting
in increased protein degradation (Schiaffino et al., 2013; Zhang
et al., 2013). Accordingly, downregulation of p-Akt and p-FoxO3
accompanied by myostatin and activin A overproduction in
the muscle were seen in mice with bladder cancer (Chen
et al., 2016), implying myostatin involvement in cachexia
triggered by various cancer types (Zimmers et al., 2002;
Chen et al., 2016). Myostatin administration is sufficient to
induce cachexia in mice through ActRIIB signaling (Costelli
et al., 2008). Conversely, blockade of the ActRIIB receptor
prevented cachexia in C26 tumor bearing mice, without affecting
increased circulating levels of IL-6, TNF-α, and IL-1β (Zhou
et al., 2010), implying ActRIIB signaling acts independent,
or downstream of inflammation-associated muscle atrophy
through autocrine expression of ActRIIB activating ligands
like myostatin or Activin-A (Trendelenburg et al., 2012). In
support of this notion, inhibition of myoblast differentiation
by inflammatory cytokines was found to require de novo
Activin-A production (Trendelenburg et al., 2012), implying
smad signaling secondary to an autocrine mechanism activated
by inflammation.
Combined, these studies identify a myriad of inflammatory
cytokines and ligands as mediators of inflammation, which
directly impact on skeletal muscle through receptor-mediated
signaling which affects muscle protein turnover in favor
of proteolysis or impairs myogenesis, ultimately resulting
in muscle wasting.
INDIRECT EFFECTS OF INFLAMMATION
In addition to the direct effects inflammatory cytokines
induced by receptor-mediated activation of signaling pathways
in skeletal muscle, cytokines also cause dysregulation of
other tissue and organ systems which indirectly contribute
to muscle wasting and cachexia development. As such,
dysregulation of the hypothalamus-pituitary-adrenal (HPA)
axis and adrenocorticoids, anorexia and malnutrition, changes
in adipocyte behavior, and hepatic metabolism have shown to
impact cachexia progression (see overview in Figure 2).
Involvement of the HPA Axis and
Corticosteroid Synthesis in Cachexia
Glucocorticoids such as cortisol are endogenous pleotropic
hormones that play an essential role in glucose mobilization and
energy metabolism, as well as having potent anti-inflammatory
immune modulatory actions (Barnes, 1998). In the 1950s,
Kendall, Reichstein and Hench received a Nobel prize for
their work in the isolation and application of the GCs
in the treatment of chronic inflammatory diseases such
as RA. Unfortunately, the clinical efficacy of endogenous
and synthetically derived GCs was tempered by severe
metabolic side effects, including osteoporosis, truncal obesity,
and muscle wasting. The mechanisms underpinning GC
induced muscle wasting are compound, with evidence of
reduced anabolic IGF-1 signaling and increased anti-anabolic
myostatin production, resulting in a reduction in the mTOR
signaling pathway, as well as induction of catabolic UPS and
autophagy mediated muscle protein degradation, secondary to
increased FOXO1 signaling (Gayan-Ramirez et al., 1999; Imae
et al., 2003; Fenton et al., 2019), and decreased myogenesis
(Pansters et al., 2013).
Due to their muscle atrophy-inducing actions, considerable
interest exists regarding possible dysregulation of endogenous
steroid synthesis in conditions such as chronic inflammation
and cancer cachexia. In particular, the HPA axis is a central
regulatory target activated in response to systemic inflammation
and stress that has been widely investigated (Ulrich-Lai et al.,
2006; Engeland et al., 2016). This critical homeostatic regulatory
pathway mediates the synthesis and release of the endogenous
GC hormone, cortisol, from the zona fasciculata of the
adrenal cortex (Silverman and Sternberg, 2012). Classically,
the HPA axis is under central circadian regulation by the
hypothalamus, where it drives a pulsatile diurnal secretion of
cortisol through the release of corticotropin-releasing hormone
(CRH) from the paraventricular nucleus. This in turn results
in the systemic release of adrenocorticotropin (ACTH) from
the anterior pituitary, which binds to the MC2R receptor
in the adrenal cortex to initiate adrenal cortisol synthesis
and release (Silverman and Sternberg, 2012; Ruggiero and
Lalli, 2016). During inflammation, pro-inflammatory factors
such as TNF-α, IL-1β, and IL-6 can act at all levels of the
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FIGURE 2 | Schematic representation of the direct and indirect effects of systemic inflammation resulting in muscle wasting. Inflammatory cytokines such as TNF-α
and IL-1β can bind to their receptors on the sarcolemma driving skeletal muscle wasting directly. Alternatively, cytokines may elicit their effects indirectly through
several mechanisms, including increased myostatin and glucocorticoid signaling, release of S100B and HMGB1 by inflamed tissue, or reduced amino acid (AA)
availability.
HPA axis to increase CRH, ACTH from the hypothalamus
and pituitary, and cortisol synthesis and release from the
adrenals (Mastorakos et al., 1993; Nolten et al., 1993; Curti
et al., 1996). Conversely, negative regulation of this pathway
is achieved through the direct suppression of CRF and
ACTH by cortisol.
In particular, focus has fallen upon the concept that
either inflammatory cytokines, or disease treatments (such as
chemotherapy in cancer) (Braun et al., 2014), cause dysregulation
of central hypothalamic/pituitary negative feedback resulting in
the over activation of the HPA axis in cachexia (Braun et al.,
2011), leading to circulating steroid excess and GC induced
muscle wasting as well as loss of adipose tissue (Crofford,
2002; Russell and Tisdale, 2005). In addition, the mixed
immunomodulatory actions that circulating GCs may mediate
in cancer immunity and in suppression of pro-inflammatory
cytokines may also influence disease progression and cachexia.
However, studies exploring the dysregulation of the HPA axis
specifically in cachexia have yielded mixed results. In mice,
several studies report increased activity of the HPA axis in
models of cancer cachexia and COPD, coinciding with weight
loss (Russell and Tisdale, 2005; Crespigio et al., 2016; Flint et al.,
2016; de Theije et al., 2018). de Theije et al. (2018) showed that
hypoxia-induced muscle wasting in a murine model of COPD
was in turn dependant on GC signaling with GC receptor/KO
mice being partly protected from muscle wasting. Several studies
in cancer patients (including colorectal, prostate, and breast)
report dysregulation of the HPA axis with increased levels of
serum cortisol (Strassmann et al., 1992; Soygur et al., 2007; Fearon
et al., 2013; Flint et al., 2016). In several of these instances,
increases in serum GCs were linked with elevated levels of the
pro-inflammatory cytokine IL-6, suggesting this may be a key
mediator of increased HPA axis activity. However, whether these
changes regulated cachexia in addition to influencing tumor
immunity was not fully elucidated (Flint et al., 2016). In addition,
muscle GC signaling was found to be required for cancer-induced
cachexia (Braun et al., 2013), and muscle atrophy in response
to inflammation-evoking cytotoxic chemotherapy was shown
to depend on intact GC signaling in skeletal muscle (Braun
et al., 2014). Similarly, muscle-specific deletion of GR prevented
endotoxin-induced muscle atrophy (Braun et al., 2013). In line,
LPS injections in rats induced an inflammatory response, body
weight loss, and muscle wasting including upregulation of FoxO
and other atrogenes (Schakman et al., 2012). In contrast to TNF-
α and NF−κB inhibitors, only inhibition of the GC receptor
using RU-486 blunted LPS-induced atrogene expression in this
model, highlighting the importance increased GC signaling
in inflammation-associated muscle wasting (Schakman et al.,
2012). Consequently, the true nature of HPA axis and steroid
dysregulation in cachexia, while of significant interest, have
proven hard to fully elucidate and show significant disease
specific variation.
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A Role for Pre-receptor Steroid
Metabolism in Glucocorticoid-Induced
Muscle Atrophy
While the systemic regulation of circulating endogenous
GC levels is determined through the HPA axis, peripheral
exposure to GCs is mediated through their tissue specific
pre-receptor metabolism. This is primarily mediated by the
11beta-hydroxysteroid dehydrogenase (11β-HSD) enzymes types
1 and 2 (Hardy et al., 2014). Here, 11β-HSD1 primarily mediates
the peripheral conversion of the inactive GC precursor cortisone,
to its active counterpart cortisol (11-DHC to corticosterone
in rodents) within target tissues, where it greatly amplifies
local GC signaling. In contrast, 11β-HSD2 solely inactivates
GCs, converting active cortisol to cortisone (corticosterone to
11-DHC in rodents) blocking local GC signaling. 11β-HSD1
shows a diverse pattern of expression across a wide array
of tissues including liver, fat, muscle, bone, and in immune
cells (Tomlinson et al., 2002; Hardy et al., 2008, 2016). In
contrast, 11β-HSD2 expression appears to be limited to tissues
such as the kidney where it protects against inappropriate
activation of the mineralocorticoid receptor by GCs (Quinkler
et al., 2005). Renewed interest in the roles of 11β-HSD1 in
inflammatory muscle wasting and cachexia have been fueled by
observations that its expression and GC activation are potently
upregulated in peripheral tissues such as muscle in response to
pro-inflammatory factors such as IL-1β and TNF-α (Ahasan et al.,
2012; Hardy et al., 2016). These studies raised the possibility that
under conditions of chronic inflammation, local amplification of
GC signaling by 11β-HSD1 may represent a critical component
in mediating inflammatory muscle wasting. This concept was
lent further credit following a seminal study by Morgan et al.
(2014) demonstrating that the systemic transgenic deletion of
11β-HSD1 in murine models of GC excess completely abrogated
GC induced muscle wasting. However, the only study to examine
the role of inflammatory 11β-HSD1 in muscle revealed a complex
interplay between the anti-inflammatory actions of GCs versus
their anti-anabolic catabolic actions (Hardy et al., 2016). Here,
while the transgenic deletion of 11β-HSD1 in murine models
of inflammatory polyarthritis resulted in reduced GC signaling
in muscle, the exacerbation of muscle inflammation drove a
more florid muscle wasting phenotype. Consequently, the role
of 11β-HSD1 in other forms of muscle wasting and cachexia
requires further investigation.
Inflammation-Driven Anorexia and
Muscle Wasting in Cachexia
Cachexia development is profoundly impacted by the
accompaniment of anorexia, categorized by reduced appetite
and nutritional deficit which ultimately leads to catabolism of
lean body and adipose tissue (Bosaeus et al., 2002). Anorexia–
cachexia is distinct from starvation, where skeletal muscle
loss is less apparent compared to adipose tissue. Adipose
tissue is a reservoir for energy, and therefore in times of
starvation or reduced energy intake, catabolism of adipose
tissue allows the release of energy which is then used in
processes that maintain skeletal muscle mass, however, in
cachectic patients both muscle and fat tissue are catabolized
as energy sources. In addition, nutritional interventions alone
are unable to reverse or alleviate this catabolic phenotype
(Moley et al., 1987; Thomas, 2002; von Haehling and Anker,
2010). Although the pathogenesis of anorexia–cachexia is
multifactorial, inflammatory cytokines have been shown to
be implicated in the development of anorexia in cachectic
patients through an amalgamation of mechanisms (Laviano
et al., 2003). In some disease states, such as cancer, tumor
burden has been implicated in driving anorexia–cachexia
through dysphagia or dysregulation of gastro-intestinal function,
ultimately leading to reduced food intake and nutritional deficit
(Ezeoke and Morley, 2015).
Rats receiving a single dose of human TNF-α resulted in
increased muscle proteolysis and anorexia (Bodnar et al., 1989;
Flores et al., 1989), while tumor bearing rats receiving TNF-α
inhibitors had markedly improved nutritional intake and body
weights (Torelli et al., 1999). These findings suggest TNF-α
indeed plays a pivotal role in inducing anorexia, although its full
contribution the development of cachexia is yet to be elucidated.
Plata-Salamán et al. (1988) demonstrated TNF-α administration
in rodents suppressed food intake in a dose-dependent manner,
through the cytokine directly acting on glucose-sensitive neurons
in the central nervous system (CNS) to suppress appetite.
Lung cancer patients exhibiting anorexia showed reduced
hypothalamic activity compared to non-anorexic patients;
however, circulating levels of pro-inflammatory cytokines such
as TNF-α, IL-6, and IL-1 were not significantly different between
groups (Molfino et al., 2017). Another cytokine implicated in
anorexia–cachexia is IL-1, with several studies observing its
effects on food intake. These anorexia-inducing effects of IL-
1 have been illustrated in several in vivo studies, with both
peripheral and central administration decreasing food intake
in rodents (Kent et al., 1994). Furthermore, Layé et al. (2000)
previously showed increases in IL-1 in the hypothalamus in
rodents upon LPS administration and reduced food intake, and
IL-1 antagonists preventing LPS-induced anorexia. However,
many of these in vivo studies also show development for tolerance
to cytokines, and therefore the interpretation of results is often
debated (Mrosovsky et al., 1989). Another study highlights
the importance of central regulation of appetite in response
to inflammation, with GLP-1 receptor antagonist mitigating
anorexia induced by LPS in rats (Grill et al., 2004).
Peripheral hormones that directly affect nutrition status
through central actions controlling appetite have also been
shown to play an important role in anorexia–cachexia. Ghrelin,
a peptide released in the gut shown to stimulate appetite, is
decreased in response to acute inflammation (Basa et al., 2003;
Otero et al., 2004). In contrast, chronic inflammation in animal
models and cachectic patients present with increased ghrelin
levels (Nagaya et al., 2001a; Shimizu et al., 2003; Dixit et al.,
2004), possibly a compensatory effect of ghrelin resistance in
cachectic and catabolic states (Li et al., 2004). Mechanisms
underpinning ghrelin’s role in anorexia–cachexia have not yet
been established; however, experimental models of cachexia have
demonstrated ghrelin administration suppressed weight loss and
alleviated skeletal muscle wasting through increased food intake
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(Nagaya et al., 2001b; Hanada et al., 2003). Another cytokine
shown to be of importance in the role of developing cachexia–
anorexia is leptin, which is released from adipocytes and signals
to the hypothalamus to regulate nutritional intake as a satiety
cue. Leptin has been shown to be increased in rodents and
humans exhibiting cachexia in many disease states, such as CHF
(Cheung et al., 2005). Therefore, the role of leptin in anorexia–
cachexia is not well established and is often speculated that the
alterations in leptin levels may be in response to malnutrition
and reduced fat mass rather than a consequence of elevated
inflammatory cytokines.
While these data collectively support a role for pro-
inflammatory cytokines in the development of anorexia, due to
cachexia’s multifactorial phenotype, it is difficult to underpin the
mechanisms in which cytokines may drive anorexia–cachexia.
However, a plethora of research indicates that energy deficits in
combination with reduced hypothalamic response may play a
pivotal role in anorexia–cachexia (Ramos et al., 2004).
Role of Inflammation-Induced
Alterations in Adipocyte and Hepatic
Metabolism in Cachexia
There is increasing evidence to show preserving adipose tissue
in cachexia can improve mortality and quality of life (Murphy
et al., 2010). Lipolysis stimulation during cachexia can be induced
by anorexia; however, there is also evidence for inflammation-
induced lipolysis. Reduction in food intake or starvation induces
lipolysis to release energy stores; however, as lipid stores are
depleted, other catabolism of tissues will ensue to provide
sufficient energy, of which a main energy source is amino acids
derived from skeletal muscle proteolysis (Finn and Dice, 2006).
As discussed previously, inflammation can induce anorexia–
cachexia, reducing food and energy intake, which ultimately leads
to the reduction of fat mass and loss of white adipose tissue
(WAT) through lipolysis. Cachexia is also associated with loss of
skeletal muscle and WAT through increased energy expenditure
(Bosaeus et al., 2001), and related to increased inflammation
in pancreatic cancer patients presenting with elevated resting
energy expenditure in addition to increased CRP levels (Falconer
et al., 1994). Patients with cancer cachexia were shown to
have increased levels of circulating IL-6 and enhanced lipolysis
compared to weight-stable cancer patients, which was not
attributed to enhanced locally expressed IL-6 levels, implicating
not the inflammatory infiltrate but other triggers for adipose
tissue wasting (Rydén et al., 2008). One mechanism that has been
described to contribute to this increased energy expenditure is
the remodeling of WAT into brown adipocytes, which has been
suggested to occur prior to skeletal muscle wasting in cancer-
cachexia (Petruzzelli et al., 2014). This increase in brown adipose
tissue increases thermogenesis in these patients (Lee et al., 2010),
which ultimately leads to an increased requirement for energy,
and thus increased energy expenditure. Interestingly, IL-6 has
been implemented in increasing uncoupling protein 1 (UCP1)
expression, a protein found in brown adipose tissue that increase
thermogenesis (Li et al., 2002). In addition, mice with syngeneic
grafts of C26 cells lacking IL-6 showed protection against weight
loss and reduced UCP1 expression compared to mice with active
IL-6 C26 cells, thus highlighting the importance of this cytokine
in WAT browning, and therefore increased energy expenditure
in cachexia (Petruzzelli et al., 2014). However, the exact role
of WAT browning in skeletal muscle loss in cachexia requires
further investigation.
Although various studies have shown the effects of
inflammatory cytokines on adipose tissue and skeletal muscle,
only few address these in the context of cachexia. Mice s.c.
injected with LLC or B16 melanoma cells showed cachexia
development, with reduced body weights, WAT loss, muscle
wasting, and increased serum TNF-α and IL-6 levels (Das
et al., 2011). Inhibition of lipolysis through genetic deletion
of adipose triglyceride lipase (Atgl), a mediator of lipolysis,
in tumor-bearing animals showed protection against cachexia
development, with reduced WAT and skeletal muscle loss.
However, TNF-α and IL-6 levels remained increased in the
serum of these animals, highlighting a possible indirect action
of these cytokines in driving cachexia and adipose tissue loss
through lipolytic mechanisms (Das et al., 2011). Importantly,
this study also emphasizes the importance of crosstalk between
adipose tissue and skeletal muscle, as inhibition of lipolysis
resulted in reduced skeletal muscle wasting, therefore suggesting
that altered free fatty acid or adipokine release may play a role
in skeletal muscle wasting. Adipose tissue secretes adipokines,
such as leptin, with endocrine functions including satiety and
whole-body metabolism (Galic et al., 2010). Several inflammatory
cytokines such as IL-6, TNF-α, and IL-1β are adipokines as well
as myokines, and have been implicated in reciprocal control of
adipose and muscle mass (Muñoz-Cánoves et al., 2013; Daas
et al., 2019) and metabolism (Piya et al., 2013). Further research,
however, is required to disentangle the role of inflammation in
adipose and muscle reciprocal effects in the context of cachexia.
Although the liver is a central regulator of metabolism,
there is relatively little research examining a role of the
liver in the association between inflammation and cachexia,
which is surprisingly considering the liver is the major site
for muscle proteolysis-derived amino acids for utilization in
gluconeogenesis and acute-phase protein synthesis, such as CRP
(Argilés et al., 2001), and elevated CRP levels are the most
frequently applied additional criteria to assess cachexia (Fearon
et al., 2006). Indeed, profound hepatic alterations are observed
prior to and during the progression of cancer cachexia, including
alterations in fat metabolism, collagen deposition, and fibrosis
(Rosa-Caldwell et al., 2020). In line, despite not evaluating
liver-anatomical changes, alterations in liver metabolism in
inflammation associated cachexia have been reported. Apcmin/+
mice with severe cachexia were shown to have increased levels
of acute phase protein haptoglobin, revealing hepatic alterations
in inflammation-associated cancer cachexia (Narsale et al.,
2015). In a model of pancreatic cancer cachexia, inhibition
of proliferator-activated receptor-alpha (PPAR-α) through IL-
6 resulted in hypoketonemia and subsequent activation of
the HPA axis, ultimately leading to increased GC release and
enhanced muscle proteolysis (Flint et al., 2016). In addition,
Goncalves et al. showed adult KrasG12D/+;Lkblf /f (KL) mice with
lung cancer and cachexia presented with increased IL-6 levels,
increased gluconeogenesis in the liver, reduced hepatic fatty acid
oxidation, and hypoketonemia. Skeletal muscle atrogenes MuRF1
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and Atrogin-1 were upregulated and also noted a decrease in
type II fiber CSA (Goncalves et al., 2018). PPAR-α inhibitor
fenofibrate restored hepatic ketogenesis, which in turn reduced
the requirement for the liver to use gluconeogenesis and alleviate
the need for type II skeletal muscle degradation for amino acids
(Goncalves et al., 2018). These results therefore show the indirect
effects of both liver metabolism and GCs on skeletal muscle
wasting in cachexia.
Myokines as a Nexus and Opportunity in
Modulating Inflammation-Associated
Cachexia
Apart from the participation of other tissues as an intermediary
step between inflammation and induction of muscle wasting, a
role for autocrine, paracrine, and even endocrine acting signals
derived from skeletal muscle in cachexia is emerging. These
concern the “myokines,” e.g., cytokines, growth factors, and other
peptide-based molecules released from skeletal muscle (Pedersen
et al., 2003). In the context of muscle mass regulation, Mstn is
a well-characterized myokine for its muscle growth-inhibitory
actions. Increased expression (Kim et al., 2018) and signaling
(Zhang et al., 2013) of Mstn in skeletal muscle may constitute
an autocrine mechanism of Mstn-dependent muscle wasting in
response to inflammatory cues. In line with this notion, blockade
of the ActRIIB receptor to inhibit Mstn signaling prevented
cachexia in C26 tumor bearing mice, without affecting increased
circulating levels of IL-6, TNF-α, and IL-1β (Zhou et al., 2010).
Interestingly, increases in muscle Mstn expression and secretion
may also contribute to muscle wasting in an endocrine route
in case of RA, as Mstn has been implied in inflammatory
bone destruction, aggravating RA-associated muscle loss (Fennen
et al., 2016). In C26 tumor-bearing BALB/c mice, involvement of
myokines was further indicated as increased muscle IL-6, IL-6R,
and myostatin expression accompanied muscle wasting in these
mice (Lee et al., 2019). Recent work has revealed GDF15 as a
myokine, which is expressed at low levels during homeostasis,
but can be induced by muscle contraction (Laurens et al.,
2020), or metabolic stress (Ost et al., 2020) or increased GDF11
levels (Jones et al., 2018) in skeletal muscle. GDF15 circulating
levels correlate inversely with skeletal muscle mass in COPD
(Patel et al., 2016), and increasing GDF15 levels are sufficient
to induce dramatic weight loss (Johnen et al., 2007). As thus
far no evidence supports the expression of the GDF15 receptor,
GFRAL, a co-receptor of the Ret tyrosine kinase, in skeletal
muscle, this suggests endocrine effects of GDF15 when secreted
as a myokine. As such, muscle derived GDF15 was reported to
stimulate lipolysis in adipocytes (Laurens et al., 2020), which
in the context of cachexia could contribute to adipose tissue
depletion. Importantly, elevation of GDF15 suppresses appetite
via activation of hypothalamic neurons (Johnen et al., 2007),
and the cachexia-inducing properties GDF15 are thought to be
a result of anorexia (Johnen et al., 2007). Although induction
of GDF15 expression by TNF-α and NF-κB regulation has been
shown for other cell types (Ratnam et al., 2017), it remains to be
explored whether GDF15 expression increases in skeletal muscle
in response to inflammatory cytokines.
In contrast, other myokines including IL-15 (Tamura et al.,
2011) and musculin (Nishizawa et al., 2004) have been attributed
anabolic effects or anti-catabolic effects on skeletal muscle, at least
in part mediated through autocrine mechanisms. In addition, IL-
6, when secreted by skeletal muscle in response to stimuli such
as exercise, exerts endocrine effects such as lipid oxidation (van
Hall et al., 2003), which contribute to organismal homeostasis.
Interestingly, in tumor-bearing mice, exercise was found to
attenuate tumor growth, which correlated with increased IL-
6 levels post-exercise, and systemic IL-6 blocking experiments
revealed IL-6 may actually contribute to hindering tumor growth
(Pedersen et al., 2016). Moreover, exercise-induced increases in
IL−6 contribute to an anti-inflammatory systemic environment,
by increasing the production of the anti-inflammatory cytokines,
IL−1β receptor antagonist (IL−1ra), and IL−10 (Steensberg
et al., 2003). A recent murine study suggested that IL-6 may
induce either pro- or anti-inflammatory actions depending on
cell source (Han et al., 2020), potentially explaining the beneficial,
suppressive effects on tumor growth and immunomodulatory
actions of muscle derived IL-6. In addition, C2C12 differentiating
myoblasts showed increased IL-6 levels during differentiation in
combination with increased STAT3 phosphorylation. Blockade of
IL-6 independently showed reduced differentiation of myotubes,
highlighting the crucial role IL-6 has in differentiating myotubes
(Hoene et al., 2012). As such, these studies may reflect an
endocrine cachexia-modulating potential of myokines.
CONCLUSION AND FUTURE
PERSPECTIVES
Despite the overwhelming preclinical evidence to imply
inflammation as both sufficient and required in disease-
associated cachexia, this has not translated into unambiguous
success of cytokine-depleting therapeutic agents to reverse
cachexia in patients with cancer or chronic disease. This
may reflect the complex interactions within an inflammatory
response, rendering a therapy based on inhibition of a single
cytokine therapy insufficient. Combined blocking approaches
(Truyens et al., 1995), or downstream inhibition of molecules
at which inflammatory cues convergence, like NF-κB (Miao
et al., 2017) or STAT3 (Ahasan et al., 2012) have shown
effective in experimental models and warrant further exploration
for pharmacological modulation. In addition, the timing
of anti-inflammatory treatment may be of key importance.
Much of the evidence in the experimental models indicates
inflammation precedes a cachectic phenotype, and anti-
inflammatory interventions successfully modulating cachexia
in preclinical studies are without exception started prior to
initiation of cachexia development. Consequently, for anti-
inflammatory agents to be effective in a clinical setting, this
may require interventions to start in patients at risk for
cachexia, i.e., “pre-cachectic,” for subsequent evaluation of
their ability to prevent or delay onset of cachexia. Bearing
time in mind as an important determinant of the efficacy
anti-inflammatory modulation, its downstream signaling should
be further considered. Feed-forward signals that transform
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inflammatory cues of systemic origin into an autocrine, muscle
atrophy-promoting signal, have been reported for Mstn (Zhang
et al., 2013) and Activin-A (Trendelenburg et al., 2012). Receptor
blocking agents for these ligands are available, and the first
clinical trials have yielded promising results in terms of safety
and efficacy in COPD patients with low muscularity (Polkey
et al., 2019). These ActRIIB inhibitors are continuously refined
(MacDonald et al., 2012), and further improvement in their
efficacy to halt or even reverse cachexia progression is anticipated
when provided as an integral part of a multimodal therapy,
i.e., combined with appropriate nutritional support and tailored
exercise programs. Similarly, desensitizing skeletal muscle to
the atrophy-inducing effects of GCs, by inhibition of local
GC-activation using therapeutic 11β-HSD1 inhibitors that are
currently in clinical trials for other applications (Harno and
White, 2010), may be a route to explore the potential of blocking
the indirect effects by which inflammation contributes to muscle
wasting. Finally, skeletal muscle tissue itself may hold the key to
counteracting inflammation driven cachexia, as myokines have
been attributed very potent immunomodulatory features, which
in future research deserve further investigation in their potential
to prevent and reverse skeletal muscle wasting in cachexia.
Combined, the extensive efforts to delineate the underlying
mechanisms of inflammation-associated cachexia have revealed
insights that provide multiple leads to evaluate novel,
more selectively targeted therapeutic approaches in this
debilitating condition.
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